Provide Pre-approval Single Patient Expanded Access (Compassionate Use) of Etrasimod for Patients.
Sponsor
Pfizer (Industry)
Overall Status
Available
CT.gov ID
NCT06025227
Collaborator
In Expanded Access, treating physicians are the Sponsors (Other)
Study Details
Study Description
Brief Summary
Provide pre-approval single patient Expanded Access (Compassionate Use) of Etrasimod for patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Detailed Description
Expanded Access requests from treating physicians may be submitted to www.pfizercares.com. Availability will depend on location and country.
Study Design
Study Type:
Expanded Access
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Patient must be intolerant, have a contraindication or had inadequate response to at least 3 therapies available for Ulcerative Colitis (UC) in this country or provide a rationale of why therapy was not used.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Pfizer
- In Expanded Access, treating physicians are the Sponsors
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Pfizer
ClinicalTrials.gov Identifier:
NCT06025227
Other Study ID Numbers:
- C504
First Posted:
Sep 6, 2023
Last Update Posted:
Sep 6, 2023
Last Verified:
Aug 1, 2023
Keywords provided by Pfizer
Additional relevant MeSH terms: